Home Health Argentina could buy the Russian vaccine to avoid a regrowth after the...

Argentina could buy the Russian vaccine to avoid a regrowth after the summer

Argentina, Brazil, Buenos Aires, China, Clinical trial, Coronavirus, COVID, Europe, India, Government, Infection, Research, Russia, Russian Federation, Science, South America, Sputnik V, Turkey, Travel, Vaccine, Virus, Vladimir Putin, World Health Organization, Russian COVID Vaccine,

The Government continues to strive to position itself in the face of what will be the demand for vaccines against the coronavirus, when the efficacy and safety of some of those currently under study is finally proven. In that sense, the Secretary of Access to Health of the Nation, Carla Vizzotti, secretly traveled to Russia to learn about Sputnik V, patented in that country in mid-August.

Sources close to the portfolio led by Ginés González García specified that The objective in the Casa Rosada is to have a reliable dose as soon as possible to avoid a re-outbreak of infections in Argentina after the summer, as is currently the case in some regions of Europe.

In this context, Sputnik V, developed by the Gamaleya Center for Epidemiological Research and Microbiology, appears as one of the options because it is in phase 3 of clinical trials and that Vladimir Putin’s administration announced that they are “ready to sell the intellectual property” of it.

Last Tuesday, in fact, The Russian authorities got ahead of many other candidates and asked the World Health Organization (WHO) authorities for the pre-classification of their vaccine against the new coronavirus SARS-CoV-2, a key step in gaining worldwide approval for distribution and use.

During the Loose Animals program, led by Luis Novaresio on the América channel, journalist Rosario Ayerdi specified that Vizzotti was accompanied by a delegation made up of other national officials, but also from the province of Buenos Aires and that on their return the Argentine envoys trusted that the doses would be available by the end of this year.

“The Buenos Aires government has already surveyed the population (and calculated that the purchase of vaccines) is going to be for the 40% of the population that will need this vaccine, there are 6 million people. They are health workers, over 60 years old, adults who are at risk, the police and teachers, so that they can return to classes in March “, he detailed.

Bilateral relations

Meanwhile, this Thursday, in the middle of a day of sessions in which several bills were discussed, the president of the Senate, Cristina Kirchner, took the time to receive in her office the Ambassador of the Russian Federation in Buenos Aires, Dmitry Feoktistov. Jorge Taiana, president of the Foreign Relations and Worship Commission of the Upper House, also participated in the meeting.

As published in The Lancet medical journal, 100% of healthy adults participating in Phase I and II clinical trials of Sputnik V demonstrated a strong immune response against SARS-CoV-2. More research will be conducted to validate those results, while Phase III is underway in Russia and other countries. This last stage will last six months and will have the participation of more than 40,000 volunteers.

Artificially created, without any element of the coronavirus in its composition, this vaccine is presented in lyophilized form, that is, as a powder that is mixed with an excipient to dissolve it and then administer it intramuscularly.

In an interview with Infobae, Dr. Nadey Hakim, vice president of the International Academy of Medical Sciences, said that “it is encouraging that more countries in South America are negotiating agreements to produce” these injections “at the local level as well as China, India, Brazil, Korea, and Turkey ”.

“The vaccine is an important tool to fight COVID-19 and save the world. This approach must be based on the best technologies available globally. Countries should have a portfolio of various vaccines and Russia’s Sputnik V should certainly be among them ”, he considered.

© The Eastern Herald

Follow us on Google News! and Flipboard!